Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CHGCF declined for three days, in of 13 cases, the price declined further within the following month. The odds of a continued downward trend are .
CHGCF moved below its 50-day moving average on December 03, 2024 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for CHGCF entered a downward trend on December 04, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on CHGCF as a result. In of 32 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CHGCF just turned positive on November 29, 2024. Looking at past instances where CHGCF's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHGCF advanced for three days, in of 8 cases, the price rose further within the following month. The odds of a continued upward trend are .
CHGCF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.490) is normal, around the industry mean (5.632). P/E Ratio (20.790) is within average values for comparable stocks, (48.974). CHGCF's Projected Growth (PEG Ratio) (16.495) is very high in comparison to the industry average of (3.004). Dividend Yield (0.020) settles around the average of (0.164) among similar stocks. P/S Ratio (5.467) is also within normal values, averaging (3.643).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHGCF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor